GE,
GSK to work on Commercial Oncology TestingRead
India-based GE Healthcare
has announced an agreement between its affiliate, Clarient Diagnostic Services
(Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access
to diagnostic testing for cancer patients by establishing a network of clinical
laboratories to identify genetic mutations associated with different tumour
types. This will help GE develop a broader laboratory and data analytics
service that will enable better efficiency in the healthcare market related to
oncology precision medicine. This will be made available as a
subscription-based service and will be operated by GE Healthcare. "Our
arrangement with GSK will enable us to leverage our clinical, technical and
quality management expertise to credential laboratory partners worldwide. This
global network of high quality diagnostic capability can be leveraged with
confidence by all pharmaceutical companies in search of rigorously standardized
oncology diagnostic services and data," said Ms Cindy Collins, CEO, Clarient.
Under the terms of the agreement GE Healthcare, through its Clarient affiliate,
will initially use its clinical laboratory, pathology, and genomics expertise,
to certify laboratories and generate diagnostic data on metastatic melanoma
patients. "Through this agreement, we hope to better address the
variability in access and quality of diagnostic testing which is a common
problem seen with targeted oncology therapies and related companion diagnostics
globally" said Mr Jonathan Pan, head of Oncology Companion Diagnostics and
Disease Strategy, GSK. He added, "The commercial testing infrastructure
created through this collaboration will enable advanced diagnostic solutions
that should improve how patient care is delivered, where the certified laboratories
are operational."
No comments:
Post a Comment